| 1.05 -0.08 (-7.08%) | 03-13 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.3 |
1-year : | 1.47 |
| Resists | First : | 1.12 |
Second : | 1.25 |
| Pivot price | 1.1  |
|||
| Supports | First : | 0.89 |
Second : | 0.74 |
| MAs | MA(5) : | 1.14 |
MA(20) : | 1.07 |
| MA(100) : | 1.17 |
MA(250) : | 1.46 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 45 |
D(3) : | 61.3 |
| RSI | RSI(14): 46.8 |
|||
| 52-week | High : | 2.56 | Low : | 0.88 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ TCRX ] has closed above bottom band by 28.8%. Bollinger Bands are 51.5% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 39 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 1.17 - 1.17 | 1.17 - 1.18 |
| Low: | 1.02 - 1.03 | 1.03 - 1.04 |
| Close: | 1.04 - 1.05 | 1.05 - 1.06 |
TScan Therapeutics, Inc., a preclinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell therapies for the treatment of patients with cancer. It is developing TSC-100 and TSC-101 for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation; and TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204 for the treatment of solid tumors. The company is also developing vaccines for infectious diseases, such as SARS-CoV-2. It has a collaboration and license agreement with Novartis Institutes for BioMedical Research, Inc., to identify novel cancer antigens from the T cells of patients with a certain specific type of cancer. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.
Sun, 15 Mar 2026
TCRX SEC Filings - Tscan Therapeutics, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Sat, 14 Mar 2026
TScan Therapeutics (NASDAQ:TCRX) Downgraded to Sell Rating by Wall Street Zen - MarketBeat
Wed, 04 Mar 2026
TCRX: Pivotal trial for relapse-preventing T-cell therapy launches in Q2, targeting major market expansion - TradingView
Wed, 04 Mar 2026
TScan Therapeutics, Inc. (TCRX) Reports Q4 Loss, Misses Revenue Estimates - Yahoo Finance
Tue, 03 Mar 2026
TScan Therapeutics, Inc. (TCRX) Posts Fourth Quarter Loss, Falls Short of Revenue Expectations - Bitget
Thu, 26 Feb 2026
TScan readies pivotal T cell trial and new 2026 studies in hematologic cancers - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 52 (M) |
| Shares Float | 47 (M) |
| Held by Insiders | 0.2 (%) |
| Held by Institutions | 65.7 (%) |
| Shares Short | 2,000 (K) |
| Shares Short P.Month | 2,360 (K) |
| EPS | -1.13 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.16 |
| Profit Margin | 0 % |
| Operating Margin | -929.5 % |
| Return on Assets (ttm) | -28.3 % |
| Return on Equity (ttm) | -71.3 % |
| Qtrly Rev. Growth | 286 % |
| Gross Profit (p.s.) | 0.19 |
| Sales Per Share | 0.19 |
| EBITDA (p.s.) | -2.54 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -135 (M) |
| Levered Free Cash Flow | -110 (M) |
| PE Ratio | -0.94 |
| PEG Ratio | 0 |
| Price to Book value | 0.48 |
| Price to Sales | 5.33 |
| Price to Cash Flow | -0.41 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|